Profile data is unavailable for this security.
About the company
Chordia Therapeutics Inc is a Japan-based drug discovery venture company mainly engaged in the research and development of novel anticancer drugs for commercialization. The Company's main business is the research and development of small molecule breakthrough drugs (first-in-class) with novel actions in the field of oncology, where there is a high unmet medical need. The Company concentrates on management and research operations (exploratory, preclinical, and clinical research), particularly in the discovery, evaluation, optimization, and clinical testing of candidate compounds, and outsources basic research, active pharmaceutical ingredient and drug product manufacturing, distribution, and sales to its various external partners to advance its business.
- Revenue in JPY (TTM)--
- Net income in JPY--
- Incorporated2017
- Employees21.00
- LocationChordia Therapeutics Inc2-26-1, Muraoka-HigashiFUJISAWA-SHI 251-0012JapanJPN
- Phone+81 366619543
- Websitehttps://www.chordiatherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jacobio Pharmaceuticals Group Co Ltd | 466.87m | -7.29bn | 25.28bn | 298.00 | -- | 1.39 | -- | 54.14 | -0.513 | -0.513 | 0.0329 | 1.26 | 0.016 | -- | 2.41 | 84,767.09 | -24.89 | -45.76 | -28.66 | -49.30 | 3.45 | -- | -1,560.88 | -372.22 | -- | -- | 0.1794 | -- | -33.66 | -- | 3.43 | -- | 19.18 | -- |
| Immunotech Biopharm Ltd | 0.00 | -6.23bn | 25.33bn | 211.00 | -- | 15.51 | -- | -- | -0.6613 | -0.6613 | 0.00 | 0.1734 | 0.00 | -- | -- | 0.00 | -35.21 | -37.42 | -55.75 | -45.48 | -- | -- | -- | -- | 0.3638 | -2.44 | 0.6119 | -- | -- | -- | -5.25 | -- | -8.46 | -- |
| Pharma Foods International Co., Ltd. | 62.15bn | 3.21bn | 25.62bn | 670.00 | 7.76 | 2.13 | 6.23 | 0.4122 | 113.47 | 113.47 | 2,185.12 | 412.69 | 1.71 | 2.10 | 14.00 | -- | 8.81 | 8.63 | 25.38 | 22.06 | 78.45 | 80.64 | 5.16 | 4.13 | 0.8875 | 81.16 | 0.5932 | 26.28 | -9.37 | 42.62 | 4.02 | 45.01 | 28.23 | -- |
| Race Oncology Ltd | 80.92m | -1.34bn | 27.41bn | -- | -- | 15.39 | -- | 338.77 | -0.0839 | -0.0839 | 0.0051 | 0.1075 | 0.0355 | -- | 0.9201 | -- | -58.97 | -46.49 | -63.04 | -48.68 | -- | -- | -1,659.82 | -2,995.74 | -- | -- | 0.00 | -- | 40.68 | 116.86 | -39.26 | -- | -- | -- |
| TOT Biopharm International Co Ltd | 19.60bn | 180.53m | 28.28bn | 551.00 | 147.04 | 1.94 | 22.12 | 1.44 | 0.0136 | 0.0136 | 1.48 | 1.03 | 0.6899 | 2.44 | 6.35 | 1,943,674.00 | 0.6356 | -20.01 | 0.8392 | -25.21 | 72.02 | 74.74 | 0.9212 | -68.53 | 1.63 | 2.98 | 0.3465 | -- | 76.54 | 81.88 | 24.36 | -- | 21.04 | -- |
| Chordia Therapeutics Inc | -100.00bn | -100.00bn | 28.88bn | 21.00 | -- | 7.27 | -- | -- | -- | -- | -- | 58.88 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 112.55 | -- | -- | -- |
| Laekna Inc | 0.00 | -5.95bn | 31.98bn | 92.00 | -- | 2.35 | -- | -- | -0.9127 | -0.9127 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -31.46 | -- | -35.71 | -- | -- | -- | -- | -- | -- | -- | 0.0856 | -- | -- | -- | 52.81 | -- | -- | -- |
| CARsgen Therapeutics Holdings Ltd | 127.67m | -13.99bn | 32.21bn | 477.00 | -- | 1.08 | -- | 252.30 | -1.37 | -1.37 | 0.0125 | 2.86 | 0.0027 | -- | 0.302 | 13,521.54 | -29.27 | -- | -32.86 | -- | 25.50 | -- | -10,960.25 | -- | 9.44 | -- | 0.1246 | -- | -- | -- | 16.19 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Simplex Asset Management Co., Ltd.as of 05 Sep 2024 | 100.80k | 0.15% |
